TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception.

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Transient Receptor Potential Vanilloid 1 (TRPV1) antagonists are being developed for chronic pain. Their rationale is well-established for inflammatory pain but less clear for conditions dominated by tactile, mechanical, and spontaneous pain.
• Preclinical data support targeting TRPV1 for bone pain, osteoarthritis, and neuropathic pain.

Purpose of the Study:

• To review the current understanding of TRPV1 antagonists for treating chronic pain conditions.
• To explore the potential of TRPV1 antagonists beyond conditions primarily involving thermal sensitivity.

Main Methods:

• Review of preclinical localization and expression studies.
• Analysis of clinical studies on TRPV1 antagonists and allelic variants.
• Evaluation of studies on tactile, mechanical, and spontaneous pain endpoints.

Main Results:

• Selective TRPV1 antagonists show limited efficacy in attenuating tactile and mechanical hypersensitivity.
• These antagonists are partially effective for behavioral and electrophysiological endpoints related to spontaneous pain.
• Human studies indicate TRPV1 antagonists can cause loss of warm thermal perception, but allelic variants suggest mediation of other sensory modalities.

Conclusions:

• TRPV1 antagonists have a clear role in inflammatory pain and show potential for osteoarthritis, bone pain, and neuropathic pain.
• Further research is needed to clarify the efficacy of TRPV1 antagonists in non-thermal chronic pain conditions.
• TRPV1 may play a role in mediating various sensory modalities beyond thermal perception.